Prashant Kudva
Vice President of Business Development | Cutting Edge Novel Nuclease Gene Editing Platform
Professional Overview
Prashant Kudva is an accomplished business development executive with extensive experience in the pharmaceutical and biotechnology industries. He specializes in driving strategic partnerships, licensing agreements, and mergers and acquisitions for innovative gene editing and rare disease therapeutics.
Experience Summary
Current Role
As the Vice President of Business Development at Emendo Biotherapeutics, Prashant is responsible for leading the company's business development strategy and collaboration efforts. He oversees the identification, evaluation, and negotiation of strategic partnerships to accelerate the commercialization of Emendo's cutting-edge novel nuclease gene editing platform, which targets previously undruggable targets.
Career Progression
Prior to joining Emendo, Prashant served as the Head of Business Development at Generian, where he was instrumental in developing and executing the company's business development strategy for its novel platform targeting previously undruggable targets. Before that, he held various business development roles at Editas Medicine, AMAG Pharmaceuticals, and leading investment banking firms, including Kaufman Hall and Stifel Financial Corp. Throughout his career, Prashant has demonstrated a strong track record of identifying and securing strategic partnerships, licensing deals, and M&A opportunities that have driven significant value for his employers.
Academic Background
Prashant holds a Bachelor of Science degree from the University of Mumbai and a Master of Business Administration from the University of Chicago Booth School of Business.
Areas of Expertise
- Gene editing and novel therapeutic platforms
- Rare disease, oncology, and ophthalmology therapeutics
- Strategic partnership and alliance management
- Licensing and deal negotiations
- Mergers and acquisitions
- Investor and stakeholder relations
Professional Impact
Prashant's deep industry knowledge, strong strategic thinking, and exceptional deal-making skills have enabled him to play a pivotal role in shaping the business development strategies of leading biotechnology companies. His contributions have directly contributed to the advancement of innovative gene editing and rare disease therapies, positively impacting patient populations in need.
Conclusion
With a proven track record of success in the biotechnology industry, Prashant Kudva is poised to continue driving value and growth for Emendo Biotherapeutics through his leadership in business development. His extensive experience, industry expertise, and strategic vision make him a valuable asset in the rapidly evolving field of gene editing and rare disease therapeutics.
